Terms: = Prostate cancer AND ARID1B, 6A3-5, 57492, ENSG00000049618, p250R, KIAA1235, ELD/OSA1, DAN15, BRIGHT, BAF250b AND Treatment
27 results:
1. Keeping your best options open with AI-based treatment planning in prostate and cervix brachytherapy.
Dickhoff LRM; Scholman RJ; Barten DLJ; Kerkhof EM; Roorda JJ; Velema LA; Stalpers LJA; Pieters BR; Bosman PAN; Alderliesten T
Brachytherapy; 2024; 23(2):188-198. PubMed ID: 38296658
[TBL] [Abstract] [Full Text] [Related]
2. Hotspots and frontiers in PSMA research for prostate cancer: a bibliometric and visualization analysis over the past 20 years.
Zhang H; Xiao L; Xie H; Li L
Eur J Med Res; 2023 Dec; 28(1):610. PubMed ID: 38115121
[TBL] [Abstract] [Full Text] [Related]
3. Application of Artificial Intelligence in Oncologic Molecular PET-Imaging: A Narrative Review on Beyond [
Mirshahvalad SA; Eisazadeh R; Shahbazi-Akbari M; Pirich C; Beheshti M
Semin Nucl Med; 2024 Jan; 54(1):171-180. PubMed ID: 37752032
[TBL] [Abstract] [Full Text] [Related]
4. Establishment and validation of preclinical models of SMARCA4-inactivated and ARID1A/arid1b co-inactivated dedifferentiated endometrial carcinoma.
Wong NKY; Llaurado Fernandez M; Kommoss FKF; Praveen Kumar P; Kim H; Liu J; Zhang G; Coatham M; Lin YY; Haegert AM; Volik S; Le Bihan S; Collins CC; Fu Y; Postovit LM; von Deimling A; Wu R; Xue H; Wang Y; Köbel M; Carey MS; Lee CH
Gynecol Oncol; 2023 Sep; 176():162-172. PubMed ID: 37556934
[TBL] [Abstract] [Full Text] [Related]
5. Towards artificial intelligence-based automated treatment planning in clinical practice: A prospective study of the first clinical experiences in high-dose-rate prostate brachytherapy.
Barten DLJ; Pieters BR; Bouter A; van der Meer MC; Maree SC; Hinnen KA; Westerveld H; Bosman PAN; Alderliesten T; van Wieringen N; Bel A
Brachytherapy; 2023; 22(2):279-289. PubMed ID: 36635201
[TBL] [Abstract] [Full Text] [Related]
6. Problem-solving skills training in adult cancer survivors: bright IDEAS-AC pilot study.
Noyes K; Zapf AL; Depner RM; Flores T; Huston A; Rashid HH; McNeal D; Constine LS; Fleming FJ; Wilding GE; Sahler OJZ
Cancer Treat Res Commun; 2022; 31():100552. PubMed ID: 35358820
[TBL] [Abstract] [Full Text] [Related]
7. IL-7 expands lymphocyte populations and enhances immune responses to sipuleucel-T in patients with metastatic castration-resistant prostate cancer (mCRPC).
Pachynski RK; Morishima C; Szmulewitz R; Harshman L; Appleman L; Monk P; Bitting RL; Kucuk O; Millard F; Seigne JD; Fling SP; Maecker HT; Duault C; Ramchurren N; Hess B; D'Amico L; Lacroix A; Kaiser JC; Morre M; Grégoire A; Cheever M; Yu EY; Fong L
J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34452927
[TBL] [Abstract] [Full Text] [Related]
8. Immunomodulatory Activity of a Colony-stimulating Factor-1 Receptor Inhibitor in Patients with Advanced Refractory Breast or prostate cancer: A Phase I Study.
Autio KA; Klebanoff CA; Schaer D; Kauh JSW; Slovin SF; Adamow M; Blinder VS; Brahmachary M; Carlsen M; Comen E; Danila DC; Doman TN; Durack JC; Fox JJ; Gluskin JS; Hoffman DM; Kang S; Kang P; Landa J; McAndrew PF; Modi S; Morris MJ; Novosiadly R; Rathkopf DE; Sanford R; Chapman SC; Tate CM; Yu D; Wong P; McArthur HL
Clin Cancer Res; 2020 Nov; 26(21):5609-5620. PubMed ID: 32847933
[TBL] [Abstract] [Full Text] [Related]
9. Thermo-responsive Fluorescent Nanoparticles for Multimodal Imaging and treatment of cancers.
Pandey N; Menon JU; Takahashi M; Hsieh JT; Yang J; Nguyen KT; Wadajkar AS
Nanotheranostics; 2020; 4(1):1-13. PubMed ID: 31911890
[TBL] [Abstract] [Full Text] [Related]
10. Long-Circulating prostate-Specific Membrane Antigen-Targeted NIR Phototheranostic Agent.
Overchuk M; Damen MPF; Harmatys KM; Pomper MG; Chen J; Zheng G
Photochem Photobiol; 2020 May; 96(3):718-724. PubMed ID: 31742696
[TBL] [Abstract] [Full Text] [Related]
11. Development and evaluation of a novel MR-compatible pelvic end-to-end phantom.
Cunningham JM; Barberi EA; Miller J; Kim JP; Glide-Hurst CK
J Appl Clin Med Phys; 2019 Jan; 20(1):265-275. PubMed ID: 30411477
[TBL] [Abstract] [Full Text] [Related]
12. [prostate brachytherapy: New techniques, new indications].
Blanchard P; Graff-Cailleaud P; Bossi A
Cancer Radiother; 2018 Jun; 22(4):352-358. PubMed ID: 29858134
[TBL] [Abstract] [Full Text] [Related]
13. Combination of MPPa-PDT and HSV1-TK/GCV gene therapy on prostate cancer.
Liang L; Bi W; Chen W; Lin Y; Tian Y
Lasers Med Sci; 2018 Feb; 33(2):227-232. PubMed ID: 29306975
[TBL] [Abstract] [Full Text] [Related]
14. A review for clinicians: prostate cancer and the antineoplastic properties of metformin.
Hankinson SJ; Fam M; Patel NN
Urol Oncol; 2017 Jan; 35(1):21-29. PubMed ID: 27836248
[TBL] [Abstract] [Full Text] [Related]
15. Targeting cancer using KAT inhibitors to mimic lethal knockouts.
Brown JA; Bourke E; Eriksson LA; Kerin MJ
Biochem Soc Trans; 2016 Aug; 44(4):979-86. PubMed ID: 27528742
[TBL] [Abstract] [Full Text] [Related]
16. Multifaceted and personalized therapy of advanced prostate cancer.
Thakur MK; Vaishampayan U
Curr Opin Oncol; 2016 May; 28(3):222-31. PubMed ID: 26992199
[TBL] [Abstract] [Full Text] [Related]
17. Immunotherapy in gastric cancer.
Matsueda S; Graham DY
World J Gastroenterol; 2014 Feb; 20(7):1657-66. PubMed ID: 24587645
[TBL] [Abstract] [Full Text] [Related]
18. A phantom study to assess accuracy of needle identification in real-time planning of ultrasound-guided high-dose-rate prostate implants.
Schmid M; Crook JM; Batchelar D; Araujo C; Petrik D; Kim D; Halperin R
Brachytherapy; 2013; 12(1):56-64. PubMed ID: 22513104
[TBL] [Abstract] [Full Text] [Related]
19. Optimizing the care of patients with advanced prostate cancer in the UK: current challenges and future opportunities.
Payne H; Bahl A; Mason M; Troup J; De Bono J
BJU Int; 2012 Sep; 110(5):658-67. PubMed ID: 22429837
[TBL] [Abstract] [Full Text] [Related]
20. prostate cancer cell lines under hypoxia exhibit greater stem-like properties.
Ma Y; Liang D; Liu J; Axcrona K; Kvalheim G; Stokke T; Nesland JM; Suo Z
PLoS One; 2011; 6(12):e29170. PubMed ID: 22216200
[TBL] [Abstract] [Full Text] [Related]
[Next]
